Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 8,614 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Infectious Disorder Clear all
Completed No phase listed Observational

Streptococcal Infection and Respiratory Distress in Newborns

NCT00612937
View directory record Official record
Conditions
Group B Streptococci, Respiratory Distress in Newborn
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
13,180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
2
States / cities
Oakland, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 23, 2026, 9:15 PM EDT
Withdrawn No phase listed Observational

A Single Center, Prospective Clinical Trial of Intravenous Ertapenem in the Treatment of Hurley Stage II or III Hidradenitis Suppurativa

NCT05255575
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ertapenem
Drug
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)

NCT02871401
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Valganciclovir, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection

NCT04439539
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
JNJ-73763989, PegIFN-alpha-2a, Tenofovir disoproxil, Tenofovir alafenamide, JNJ-56136379
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Pittsburgh, Pennsylvania • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 4 Interventional

Long-Term Lamivudine Therapy for Chronic Hepatitis B

NCT00120354
View directory record Official record
Conditions
Hepatitis B, Chronic
Interventions
Blood Testing, Percutaneous Liver Biopsy, Lamivudine Therapy
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 9:15 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Assessing the Safety of Pregnancy In the CoRonavirus (COVID-19) pandEmic

NCT04388605
View directory record Official record
Conditions
Corona Virus Infection, COVID, Pregnancy Related, Early Pregnancy
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Female only
Enrollment
7,965 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa.

NCT03248531
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
11
States / cities
Los Angeles, California • Coral Gables, Florida • Orange, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 23, 2026, 9:15 PM EDT
Withdrawn Phase 1 Interventional

Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma

NCT02378922
View directory record Official record
Conditions
AIDS-Related Hodgkin Lymphoma, AIDS-Related Non-Hodgkin Lymphoma, HIV Infection, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma
Interventions
Gene-Modified HIV-Protected Hematopoietic Stem Cells, Laboratory Biomarker Analysis, Transplant Conditioning
Biological · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 66 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 23, 2026, 9:15 PM EDT
Completed No phase listed Observational

Central Venous Catheter Insertion Train the Trainer

NCT02402257
View directory record Official record
Conditions
Healthy
Interventions
CVC Train the Trainer
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 3 Interventional

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

NCT00404612
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 23, 2026, 9:15 PM EDT
Recruiting No phase listed Observational

SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

NCT00187512
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
2,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2033
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 9:15 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluating Modes of Influenza Transmission 2b Baseline SAR

NCT07342556
View directory record Official record
Conditions
Influenza (Healthy Volunteers)
Interventions
Exposure to Donors with naturally acquired influenza virus infection
Other
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 49 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
College Park, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Peer-Oriented HIV Prevention Outreach Program for Individuals at High Risk for HIV and Other STIs

NCT00183456
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases
Interventions
Peer-oriented intervention, Group cognitive behavioral therapy (CBT)
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 74 Years
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2013 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations

NCT04761822
View directory record Official record
Conditions
SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
Interventions
Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
5 Years and older
Enrollment
746 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
29
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Oct 23, 2026, 9:15 PM EDT
Withdrawn Not applicable Interventional

Preoperative Optimization to Improve Functional Status

NCT04566172
View directory record Official record
Conditions
Pulmonary Atelectasis, Pneumonia, Ventilator-Associated
Interventions
Inspiratory Muscle Training (IMT)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
65 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Pharmacokinetics of Recombinant Human CD4 Immunoglobulin (rCd4-IgG) Administered by Intravenous Bolus in Patients With AIDS and AIDS Related Complex

NCT00000675
View directory record Official record
Conditions
HIV Infections
Interventions
CD4-IgG
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:15 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

ARMOR Study: COVID-19 Seroprevalence Among Healthcare Workers

NCT04367857
View directory record Official record
Conditions
Covid-19, Coronavirus Infection, Coronavirus
Interventions
COVID-19 Serology, Health Care Worker Survey
Other · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 4 Interventional Results available

Efficacy Study of Substitution of Darunavir/Ritonavir (DRV/r) for Dual-boosted Protease Inhibitors

NCT00543101
View directory record Official record
Conditions
HIV Infections
Interventions
Darunavir (DRV/r), continue on current dual boosted PI
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 2 Interventional

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

NCT03897257
View directory record Official record
Conditions
Tinea Pedis
Interventions
UHE-103A1 cream, UHE-103A2 cream, UHE-103B cream, UHE-103A1B cream, UHE-103A2B cream
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
San Diego, California • Melbourne, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Phase 3 Interventional Results available

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis

NCT02748512
View directory record Official record
Conditions
Non-Infectious Uveitis
Interventions
FAI Insert administered using the Mk II inserter, FAI Insert administered using the Mk I inserter
Drug
Lead sponsor
EyePoint Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
6
States / cities
Colorado Springs, Colorado • Waltham, Massachusetts • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Not applicable Interventional

Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study

NCT00002037
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Trifluridine
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:15 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Immunotherapeutic Activity of an Anti-PD-1 Antibody (Cemiplimab) in Participants With HIV-1 on Suppressive cART

NCT03787095
View directory record Official record
Conditions
HIV Infections
Interventions
Cemiplimab, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Not applicable Interventional

A Study of Delavirdine Used Together With Other Anti-HIV Drugs in HIV-Infected Patients

NCT00002401
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Delavirdine mesylate, Lamivudine, Zidovudine
Drug
Lead sponsor
Pharmacia and Upjohn
Industry
Eligibility
14 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Peapack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 23, 2026, 9:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Famciclovir 500 mg Tablets Under Fed Conditions

NCT01321502
View directory record Official record
Conditions
Herpes
Interventions
famciclovir
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 23, 2026, 9:15 PM EDT